Volume 6.27 | Jul 17

Cord Blood News 6.27 July 17, 2014
Cord Blood News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Cord Blood News on Twitter
 
TOP STORY
IL-12 Secreting CD19-Targeted Cord Blood-Derived T Cells for the Immunotherapy of B Cell Acute Lymphoblastic Leukemia
Scientists developed a novel strategy to expand umbilical cord blood T cells to clinically relevant numbers in the context of exogenous cytokines. [Leukemia] Abstract
Request Sample: ReLeSR™, Easy Passaging Through Selective Detachment of hPSCs
 
PUBLICATIONS (Ranked by impact factor of the journal)
Asymmetric Aneuploidy in Mesenchymal Stromal Cells Detected by In Situ Karyotyping and Fluorescence In Situ Hybridization: Suggestions for Reference Values for Stem Cells
Researchers investigated the frequency of cytogenetic aberrations in mesenchymal stromal cells (MSCs) using G-banding and fluorescence in situ hybridization and suggest reference values for aneuploidy in MSCs. Cytogenetic analysis was performed on 103 consecutive cultures from 68 MSCs (25 adipose-origin, 20 bone marrow-origin, 18 cord blood-origin, and five neural stem cells; eight from adipose tissue of patients with breast cancer and 60 from healthy donors). [Stem Cells Dev] Abstract

Outcomes after Hematopoietic Stem Cell Transplant for Children with I-Cell Disease
Although hematopoietic stem cell transplant (HSCT) has been used to successfully treat some lysosomal storage diseases, there have been only two case reports in the use of HSCT to treat mucolipidosis type II (MLII) or I-cell disease. Scientists describe the combined international experience in the use of HSCT for MLII in 22 patients. [Biol Blood Marrow Transplant] Abstract

Effect of CD8+ Cell Content on Umbilical Cord Blood Transplantation in Adults with Hematological Malignancies
This single center, cohorts study included patients with hematological malignancies who received umbilical cord blood transplantation after myeloablative conditioning regimen. [Biol Blood Marrow Transplant] Abstract

Qualitative and Quantitative Comparison of the Proteome of Erythroid Cells Differentiated from Human iPSCs and Adult Erythroid Cells by Multiplex TMT Labelling and NanoLC-MS/MS
The authors analyzed the proteome of erythroid cells differentiated from the induced pluripotent stem cells (iPSC) fibroblast derived line and showed they express hallmark red blood cell proteins, including all those of the ankyrin and 4.1R complex. They next compared the proteome of erythroid cells differentiated from three iPSC lines with that of adult and cord blood progenitors. [PLoS One] Full Article

Outcome of Patients with HTLV-1-Associated Adult T-Cell Leukemia/Lymphoma after SCT: A Retrospective Study by the EBMT LWP
Experience with allo-SCT for adult T-cell leukemia/lymphoma (ATL) appears encouraging but is limited to Japanese series. Researchers indicate that allo-SCT but not auto-SCT may salvage a subset of ATL patients, supporting the existence of graft vs ATL effect also in non-Japanese patients. [Bone Marrow Transplant] Abstract

Non-Myeloablative Peripheral Blood Haploidentical Stem Cell Transplantation for Refractory Severe Aplastic Anemia
Researchers report our pilot findings with haploidentical stem cell transplantation using uniform reduced intensity conditioning with post graft high dose cyclophosphamide in eight patients with refractory severe aplastic anemia or patients who rejected a prior unrelated donor or cord blood transplant. [Biol Blood Marrow Transplant] Abstract

Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies from Mismatched 9/10 HLA Unrelated Donors: Comparison with Transplantations from 10/10 Unrelated Donors and HLA Identical Siblings
The authors retrospectively studied the outcome of 213 consecutive patients who received allo-HSCT for hematological malignancies, 121 from HLA identical siblings, 63 from 10/10 HLA identical unrelated donors and 29 from 9/10 HLA mismatched unrelated donors in their institution. [Leuk Lymphoma] Abstract

Register for new mouse/rat HSC CFU training course.
 
REVIEWS
Recent Advances in the Management of Graft-versus-Host Disease
Better understanding of its pathobiology is facilitating the development of biomarkers for the severity of acute graft-versus-host disease (GvHD) and treatment response, and has led to the introduction of a more prognostically relevant grading system for chronic GvHD. [Arch Dis Child] Abstract

Visit our reviews page to see a complete list of reviews in the cord blood research field.

Accelerate Your Cell Therapy to Market - Cell Therapy Bioprocessing 2014
 
INDUSTRY NEWS
Biotech Company Receives Application Approval from Chinese Food and Drug Administration
Beike Biotechnology Co., Ltd. has officially been accepted into the approval process for the Chinese Food and Drug Administration for the use of human umbilical cord derived mesenchymal stem cells for clinical translation and treatment of systemic lupus erythematosus. [Beike Biotechnology Co., Ltd. (PR Newswire Association LLC)] Press Release

Cellular Dynamics Awarded Patents Covering Derivation of Pluripotent Stem Cells from Fresh or Banked Human Blood Samples
Cellular Dynamics International, Inc. announced that the U.S. Patent and Trademark Office awarded the company three patents on the reprogramming of human cells into pluripotent stem cells from human blood. [Cellular Dynamics International, Inc.] Press Release

From our sponsor:
View immunology lectures, protocols and other resources on the
Human Immunology Portal.
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW Translational Regenerative Medicine (TRM) Congress 2014
October 21-22, 2014
Leipzig, Germany

Visit our events page to see a complete list of events in the cord blood community.
 
JOB OPPORTUNITIES
NEW Product Marketing Manager (Cesca Therapeutics)

NEW Postdoctoral Fellow – Fetal Imprinting and Establishment of the Methylome in Cord Tissue and Placenta (University of Freiburg)

NEW Research Associate – Localization of the Placenta (University College London)

Hematology Investigator (Case Western Reserve University)

Cord Tissue Processing Technician (Cord Blood Registry)

Clinical HSCT Faculty Position (University of Wisconsin School of Medicine and Public Health)

Postdoctoral Position – Hematopoietic Stem Cell Research (UT Southwestern Medical Center at Dallas)

Research Associate – Hematology/Oncology (University of Chicago)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Cord Blood News: Archives | Events | Contact Us